TB Alliance

FDA Antimicrobial Drugs Advisory Committee recommends approval of pretomanid

Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.

Read More →

TB, among the oldest infectious diseases, is now the world’s deadliest – It’s Time to invest in solutions

GENEVA  (May 22, 2019) - This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health and product development to urge increased global funding and action to eradicate tuberculosis (TB). Today, delegates are assessing progress made since last year’s UN High Level Meeting (HLM) on TB as well as the 2017 HLM on Antimicrobial Resistance (AMR).

Read More →

TB Alliance and partners form multidisciplinary center for translational TB drug research

NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center of Excellence in Translational Research (CETR) grant (U19AI142735) for tuberculosis (TB) drug development. New translational research to develop novel anti-TB medicines is being carried out with partners at the University of Illinois at Chicago, Harvard University, Johns Hopkins University, and Research Triangle Institute.

Read More →

TB Alliance and Mylan announce global collaboration to commercialize investigational drug pretomanid as part of two regimens to treat TB

NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).

Read More →

TB medicine pretomanid enters regulatory review process in the United States

NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for the use of pretomanid as part of a new regimen, in combination with bedaquiline and linezolid, for the treatment of extensively drug-resistant (XDR) TB, treatment intolerant multidrug-resistant (MDR) TB, and treatment non-responsive MDR-TB.

Read More →

Schrödinger and TB Alliance announce collaboration to accelerate TB drug discovery

Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments

Read More →

TB Alliance receives GHTC Partnership Award for development of child-friendly TB medicines

[November 28, 2018, WASHINGTON, D.C.] – TB Alliance and partners were honored today as the winner of the Global Health Technologies Coalition (GHTC) 2018 Innovating for Impact Partnership Award, for the development of improved child-friendly tuberculosis (TB) medicines. Since the improved medicines were introduced in 2016, 85 countries have procured more than 800,000 treatment courses. Appropriately-dosed and palatable, these new medicines are improving TB treatment and survival for the estimated one million children stricken with TB each year.

Read More →

TB Alliance joins Innovative Medicines Initiative to accelerate development of new TB cures

[October 24, 2018, NEW YORK] - TB Alliance has joined the Innovative Medicines Initiative (IMI) as an Associated Partner on programs focused on antimicrobial resistance and innovation in clinical trials. IMI is a public-private partnership between the European Union and the European pharmaceutical industry that facilitates the development of medicines, especially in areas of unmet medical need including tuberculosis (TB). 

Read More →

TB Alliance and Liverpool School of Tropical Medicine collaborate to develop new TB therapies

LIVERPOOL (September 19, 2018) – The Liverpool School of Tropical Medicine (LSTM) and TB Alliance are collaborating to investigate novel combination drug therapies that could help the fight against multidrug-resistant tuberculosis (MDR-TB), following an award of £1 million from the Medical Research Council.

Read More →

SimpliciTB clinical trial launched with first patients in Tbilisi, Georgia

NEW YORK, NY (August 28, 2018)—TB Alliance has initiated a pivotal clinical trial, SimpliciTB (pronounced: sim-plis-i-tee-bee), that will evaluate whether a new four-drug regimen can treat most types of tuberculosis (TB) including multidrug-resistant TB (MDR-TB) more quickly and effectively than currently-available treatments. The first patients have been enrolled at the National Center for Tuberculosis and Lung Disease in Tbilisi, Georgia. SimpliciTB is expected to enroll 450 people with TB, including up to 150 with MDR-TB* across at least 26 centers in 10 countries in Africa, Asia, Europe and Latin America.

Read More →

Page 1 of 7 · Total posts: 10

1 2 Last→